South Korea · Delayed Price · Currency is KRW PharmaResearch Statistics
Total Valuation
PharmaResearch has a market cap or net worth of KRW 6.46 trillion. The enterprise value is 6.22 trillion.
| Market Cap | 6.46T |
| Enterprise Value | 6.22T |
Important Dates
The last earnings date was Tuesday, August 12, 2025.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
PharmaResearch has 10.39 million shares outstanding. The number of shares has increased by 2.29% in one year.
| Current Share Class | 10.39M |
| Shares Outstanding | 10.39M |
| Shares Change (YoY) | +2.29% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.19% |
| Owned by Institutions (%) | 14.66% |
| Float | 9.19M |
Valuation Ratios
The trailing PE ratio is 50.81 and the forward PE ratio is 30.80. PharmaResearch's PEG ratio is 0.63.
| PE Ratio | 50.81 |
| Forward PE | 30.80 |
| PS Ratio | 14.37 |
| PB Ratio | 10.13 |
| P/TBV Ratio | 11.18 |
| P/FCF Ratio | 57.08 |
| P/OCF Ratio | 43.73 |
| PEG Ratio | 0.63 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 33.74, with an EV/FCF ratio of 54.92.
| EV / Earnings | 48.96 |
| EV / Sales | 13.82 |
| EV / EBITDA | 33.74 |
| EV / EBIT | 36.74 |
| EV / FCF | 54.92 |
Financial Position
The company has a current ratio of 7.76, with a Debt / Equity ratio of 0.33.
| Current Ratio | 7.76 |
| Quick Ratio | 6.75 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | 1.14 |
| Debt / FCF | 1.85 |
| Interest Coverage | 17.73 |
Financial Efficiency
Return on equity (ROE) is 20.92% and return on invested capital (ROIC) is 15.20%.
| Return on Equity (ROE) | 20.92% |
| Return on Assets (ROA) | 13.87% |
| Return on Invested Capital (ROIC) | 15.20% |
| Return on Capital Employed (ROCE) | 20.05% |
| Revenue Per Employee | 999.58M |
| Profits Per Employee | 282.21M |
| Employee Count | 450 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 2.05 |
Taxes
In the past 12 months, PharmaResearch has paid 36.38 billion in taxes.
| Income Tax | 36.38B |
| Effective Tax Rate | 23.27% |
Stock Price Statistics
The stock price has increased by +252.61% in the last 52 weeks. The beta is 0.60, so PharmaResearch's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | +252.61% |
| 50-Day Moving Average | 597,050.00 |
| 200-Day Moving Average | 389,007.00 |
| Relative Strength Index (RSI) | 46.59 |
| Average Volume (20 Days) | 89,016 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaResearch had revenue of KRW 449.81 billion and earned 126.99 billion in profits. Earnings per share was 12,241.81.
| Revenue | 449.81B |
| Gross Profit | 332.86B |
| Operating Income | 169.23B |
| Pretax Income | 156.37B |
| Net Income | 126.99B |
| EBITDA | 184.30B |
| EBIT | 169.23B |
| Earnings Per Share (EPS) | 12,241.81 |
Balance Sheet
The company has 481.06 billion in cash and 209.62 billion in debt, giving a net cash position of 271.44 billion or 26,126.11 per share.
| Cash & Cash Equivalents | 481.06B |
| Total Debt | 209.62B |
| Net Cash | 271.44B |
| Net Cash Per Share | 26,126.11 |
| Equity (Book Value) | 638.13B |
| Book Value Per Share | 58,862.69 |
| Working Capital | 533.91B |
Cash Flow
In the last 12 months, operating cash flow was 147.77 billion and capital expenditures -34.55 billion, giving a free cash flow of 113.22 billion.
| Operating Cash Flow | 147.77B |
| Capital Expenditures | -34.55B |
| Free Cash Flow | 113.22B |
| FCF Per Share | 10,897.08 |
Margins
Gross margin is 74.00%, with operating and profit margins of 37.62% and 28.23%.
| Gross Margin | 74.00% |
| Operating Margin | 37.62% |
| Pretax Margin | 34.76% |
| Profit Margin | 28.23% |
| EBITDA Margin | 40.97% |
| EBIT Margin | 37.62% |
| FCF Margin | 25.17% |
Dividends & Yields
This stock pays an annual dividend of 1,100.00, which amounts to a dividend yield of 0.18%.
| Dividend Per Share | 1,100.00 |
| Dividend Yield | 0.18% |
| Dividend Growth (YoY) | 15.79% |
| Years of Dividend Growth | 5 |
| Payout Ratio | 9.46% |
| Buyback Yield | -2.29% |
| Shareholder Yield | -2.12% |
| Earnings Yield | 1.97% |
| FCF Yield | 1.75% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PharmaResearch has an Altman Z-Score of 8.34 and a Piotroski F-Score of 7.
| Altman Z-Score | 8.34 |
| Piotroski F-Score | 7 |